Dec 05, 2019
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Nov 14, 2019
NGM Bio to Present at the Stifel 2019 Healthcare Conference
Nov 12, 2019
NGM Reports Business Highlights and Third Quarter 2019 Financial Results
Oct 29, 2019
NGM Bio Announces Appointment of Valerie Pierce as General Counsel
Oct 18, 2019
NGM Bio to Present at Upcoming Investor Conferences
Oct 07, 2019
NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH
Oct 06, 2019
NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH
Oct 03, 2019
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting®
Aug 12, 2019
NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
Jun 10, 2019
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
Jun 05, 2019
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
May 16, 2019
NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results
Apr 08, 2019
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
Apr 03, 2019
NGM Bio Announces Pricing of Initial Public Offering
Mar 20, 2019
NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer
Mar 20, 2019
Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022
Jan 03, 2019